FlandersBio on Twitter

Follow us on Twitter

Archive for May 2015 - News

Archive for May 2015 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

ABLYNX TO PRESENT AT THE ANNUAL JEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE

28.05.2015

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announces it will present at the Annual Jefferies 2015 Global Healthcare Conference in New York City on Thursday, 4 June 2015 at 09:30 a.m. EST (03:30 p.m. CET). read more

TiGenix: Safety and tolerability of Cx611 confirmed in Phase I sepsis challenge trial

28.05.2015

TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today that the results of its Phase I sepsis challenge trial of Cx611 confirm safety and tolerability. read more

Pepric appoints Dr. Enrico Bastianelli as independent Director

27.05.2015

The General Assembly of Pepric appointed Dr. Enrico Bastianelli as independent non-executive Board member. Dr. Bastianelli is the CEO of Bone Therapeutics since 2006, a cell therapy company for bone fracture repair and prevention. Previously, Dr. Bastianelli gained a tremendous expertise in the cell and pharmaceutical industry based on many years of experience at Procter and Gamble Pharmaceuticals, McKinsey & Co and ProSkelia. read more

New insights could result in changes to the therapeutic strategy to combat Alzheimer’s

27.05.2015

A typical characteristic of the brain of an Alzheimer sufferer is the presence of insoluble Tau protein aggregates. Scientists at VIB, KU Leuven and Janssen Pharmaceutica have demonstrated that the distribution of these aggregates through the brain is facilitated by synaptic connections between brain cells. This news is highly significant because the focus is increasingly on repairing synaptic connections as a therapeutic strategy in neurodegenerative diseases such as Alzheimer’s. In fact, it is generally accepted that a loss of synaptic connections leads to a loss in cognitive skills. read more

Galapagos receives transparency notifications

27.05.2015

Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from the Capital Group Companies, Inc., Fidelity Management and Research LLC, and Federated Equity Management Company of Pennsylvania. read more

Biocartis and Fast-track diagnostics sign strategic collaboration in infectious diseases

27.05.2015

Biocartis (Euronext Brussels: BCART), an innovative molecular diagnostics company and Fast-track diagnostics, a leading provider of multiplex polymerase chain reaction (PCR) test kits for infectious disease, announced today that they have entered into a strategic collaboration to develop a range of multiplex infectious disease tests to run on the Biocartis Idylla™ system. read more

ThromboGenics Q1 2015 Business Update

26.05.2015

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today issues a business and financial update for the three months ending 31 March, 2015. read more

VIB and Performa Investimentos establish GlobalYeast to deliver superior industrial yeast strains for the bio based economy

26.05.2015

VIB, a leading life sciences institute in Flanders, and Performa Investimentos, an independent Brazilian private equity and venture capital company, today announced the establishment of GlobalYeast, a new company that will develop and deliver superior industrial yeast strains for bioethanol and the green chemicals industry. The company raised a total of 6.25 M EUR from an investor consortium composed of a Brazilian VC Fund (Performa Investimentos), two Belgian funds (Gemma Frisius and SOFI) and VIB and will focus on the Brazilian market and large groups worldwide. read more

TAUBE HODSON STONEX PARTNERS LLP ANNOUNCE 4.35% SHAREHOLDING IN ABLYNX

26.05.2015

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Taube Hodson Stonex Partners LLP. read more

Tara Oceans expedition sheds light on the world of plankton

26.05.2015

When thinking of the “lungs of the world”, everyone spontaneously thinks of the tropical rain forest; but that’s not giving our oceans any credit. The fact is, plankton is our most important source of oxygen. This is only one of the reasons why it is so important to examine plankton and understand how this diversity of microorganisms works. It was with this objective in mind that a large international team of scientists, including Jeroen Raes (VIB/KU Leuven/Vrije Universiteit Brussel), was involved in the Tara Oceans expedition. The schooner Tara left for an around-the-world voyage between 2009 and 2013. During this trip, the scientists collected and analyzed thousands of samples from our oceans. The first results will be published in a special edition of Science on May 22. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print